BeiGene Ltd.

ISIN US07725L1026

 | 

WKN A1437N

Market cap (in EUR)
27,032.60 m
Country
Cayman Islands
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Cayman Islands

Financials

Key metrics

Market capitalisation, EUR 27,032.60 m
EPS, EUR -3.46
P/B ratio 7.61
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 3,522.47 m
Net income, EUR -596.09 m
Profit margin -16.92%

What ETF is BeiGene Ltd. in?

There are 9 ETFs which contain BeiGene Ltd.. All of these ETFs are listed in the table below. The ETF with the largest weighting of BeiGene Ltd. is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.